BEIJING, Aug. 15 (Xinhua) -- Yantai Dongcheng Biochemicals Co., Ltd. (002675.SZ) announced on Wednesday that it will build a nuclear medicine center in east China’s Shanghai.
According to a filing to the stock exchange, the center is expected to cover an area of 48 mu (15 mu equal one hectare). It will focus mainly on the R&D of the radioactive drugs and meanwhile work as an industrial base of nuclear medicine.
Establishment of the center will further strengthen construction of its R&D and technological innovation system, said Dongcheng Biochemicals, the only listed company focusing on the nuclear medicine in China’s A-share market. (Edited by Li Wenxin, hupingchao@xinhua.org)
A single purchase
